Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
Open Access
- 6 March 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 39 (4), 473-475
- https://doi.org/10.1007/s40273-021-01005-w
Abstract
No abstract availableFunding Information
- GW Research Ltd
This publication has 23 references indexed in Scilit:
- Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility AnalysisPharmacoEconomics, 2018
- Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver surveyEpilepsy & Behavior, 2018
- Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2018
- Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical ConsiderationsFrontiers in Neurology, 2017
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet SyndromeNew England Journal of Medicine, 2017
- Lennox–Gastaut Syndrome: A State of the Art ReviewNeuropediatrics, 2017
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJama-Journal Of The American Medical Association, 2016
- Lennox–Gastaut syndrome: impact on the caregivers and families of patientsJournal of Multidisciplinary Healthcare, 2014
- PND22 ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH LENNOX-GASTAUT SYNDROMEValue in Health, 2008
- Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsyNeurology, 1998